Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P144 for Skin Fibrosis in Systemic Sclerosis
NCT00574613Phase 2Completed
- Sponsor
- ISDIN
- Start
- Sep 2007
- Primary completion
- Nov 2009
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Disitertide with Placebo (2 arms). Primary endpoint: Percentage of reduction in the soluble collagen content and skin hardness at 3 months. Started Sep 2007; status: completed.
02
Drugs
disitertide
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00574613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00574613.